Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market. The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Key takeaways

Quick scan — what you need to know:

• The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
• The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything
• currently on the market. The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster
• and better than anything currently on the market.

Background

What led here, in plain terms:

• eration allergy treatment that may prove to work faster and better than anything currently on the market.
• Full context often emerges as officials, markets, or courts add updates.

Why it matters

Why readers and decision-makers should care:

• The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
• The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything
• currently on the market. The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster